Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.

NCT04483505

Last updated date
Study Location
Institut Català d'oncologia - Hospital Duran I Reynals
Hospitalet de Llobregat, Barcelona, 08908, Spain
Contact
+34917328000

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

+34917328000

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Breast Cancer Metastatic, Hormone Receptor Positive Malignant Neoplasm of Breast
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Women ≥18 years-old.

2. Diagnostic of metastatic or locally advanced non-resectable breast cancer.

3. Ability to understand and signing of the PIS/ICF for FGFR testing. FGFR testing will be performed centrally at CNIO (RNAscope and FISH).

4. Ability to understand and signing the written PIS/ICF for study treatment eligibility.

5. Availability of fresh tumor biopsy specimen for FGFR1/3 mRNA expression and FISH testing.

6. Hormone-receptor positivity defined by at least 5% positivity of ER and/or PR (no central laboratory testing is required).

7. Positivity of FGFR1/2/3 by RNA-scope and/or FISH.

8. Patients must have undergone a previous hormonal treatment line for metastatic disease, with anastrozole, letrozole or exemestane, plus a cell cycle inhibitor (palbociclib, ribociclib or abemaciclib).

9. Recovery of toxicities from previous regimens to equal or below tolerable grade II.

10. HER2-negativity (Herceptest 0+, 1+ or 2+ with negative FISH/CISH/SISH).

11. ECOG performance status of 0/1.

12. Life expectancy of >24 weeks.

13. Adequate bone marrow, liver and renal function as assessed by laboratory requirements:

1. Absolute neutrophil count (ANC) ≥ 1,500/mm3

2. Hemoglobin ≥ 10 g/dL (without transfusion or erythropoietin .

3. Platelet count ≥ 100,000/mm3

4. Total bilirubin ≤ 1.5 × the upper limit of normal (ULN).

5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN

6. Alkaline phosphatase ≤ 2.5 times ULN

7. Lipase and amylase ≤ 2 × ULN.

8. Serum albumin ≥ 2.5 g/dl.

9. Glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m2

14. INR ≤ 1.5 × ULN and PTT or activated PTT (aPTT) ≤ 1.5 × ULN.

15. Negative serum pregnancy test in women of childbearing potential.

16. Women of reproductive potential must agree to use highly effective contraception when sexually active.

17. Evaluable disease according to RECIST 1.1 criteria.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Involvement in the planning and/or conduct the study.


2. Previous enrollment in the present study.


3. Previous or concurrent cancer except:


1. Cervical carcinoma in situ.


2. Treated basal-cell carcinoma or squamous cell skin cancer.


3. Any other cancer curatively treated > 3 years before the first study drug
administration.


4. Receipt the last dose of anticancer therapy at least 21 days prior to the first dose
of study drug.


5. Acute toxic effects of previous anticancer chemotherapy or immunotherapy have to be
normalized completely


6. Anti-cancer therapy is defined as any agent or combination of agents with clinically
proven anti-tumor activity


7. Previous treatment with anti-FGFR directed therapies.


8. Irradiation of single bony lesions with risk of fracture. Zoledronic acid or denosumab
started prior to trial registration is allowed.


9. Symptomatic metastatic brain or meningeal tumors.


10. History or current condition of an uncontrolled cardiovascular disease including any
of the following conditions:


1. Congestive heart failure, unstable angina (symptoms of angina at rest) or


2. New-onset angina


3. Myocardial infarction (MI).


4. Unstable cardiac arrhythmias requiring anti-arrhythmic therapy.


5. Patients with known coronary artery disease, congestive heart failure not meeting
the above criteria, must be on a stable medical regimen.


11. Known human immunodeficiency virus (HIV) infection.


12. Active hepatitis B virus or hepatitis C infection requiring treatment.


1. Patients with past HBV infection or resolved HBV infection are eligible if HBV
DNA is negative.


2. Patients positive for hepatitis C virus are eligible only if polymerase chain
reaction is negative for HCV RNA.


13. Any condition that in the opinion of the investigator would interfere with evaluation
of study treatment or interpretation of patient safety or study results, or inability
to comply with the study and follow-up procedures.


14. Previous or concomitant participation in another clinical study with investigational
medicinal products.


15. Active tuberculosis.


16. Clinically active infections.


17. Treatment with therapeutic oral or i.v. antibiotics.


18. Patients receiving prophylactic antibiotics are eligible.


19. Seizure disorder requiring medication.


20. History of organ allograft.


21. Evidence or history of bleeding diathesis or coagulopathy.


22. Any hemorrhage / bleeding event CTCAE v.5.0 ≥ Grade 3.


23. Serious, non-healing wound, ulcer or bone fracture.


24. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in
the formulation.


25. Any malabsorption condition.


26. Current diagnosis of any retinal disorders including retinal detachment, retinal
pigment epithelial detachment (RPED), serous retinopathy or retinal vein occlusion.


27. Peripheral sensory neuropathy of CTCAE v.5.0 Grade 2 or higher.


28. Current evidence of endocrine alteration of calcium phosphate homeostasis.


29. Concomitant therapies that are known to increase serum phosphate levels.


30. Any condition that is unstable or could jeopardize the safety of the patient and their
compliance in the study.


31. Breast-feeding.


32. Use of strong inhibitors of CYP3A4 and strong inducers of CYP3A4.


33. Autologous bone marrow transplant or stem cell rescue.


34. Major surgery, open biopsy or significant traumatic injury.


35. Renal failure requiring peritoneal dialysis or hemodialysis.


36. Systolic/diastolic blood pressure ≤ 100/60 mmHg and concurrent heart rate ≥ 100/min.


37. Inability to swallow oral tablets.


38. Close affiliation with the investigational site; e.g. a close relative of the
investigator or a dependent person.


39. Substance abuse, medical, psychological or social conditions that may interfere with
the patient's participation in the study or evaluation of the study results.


40. Arterial or venous thrombotic events or embolic events such as cerebrovascular
accident, deep vein thrombosis or pulmonary embolism.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Breast Cancer Metastatic, Hormone Receptor Positive Malignant Neoplasm of BreastRogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.
NCT04483505
  1. Hospitalet de Llobregat, Barcelona
  2. Fuenlabrada, Madrid
  3. Pozuelo De Alarcón, Madrid
  4. Lleida,
  5. Madrid,
  6. Madrid,
  7. Madrid,
  8. Valencia,
Female
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.
Official Title  ICMJE Rogaratinib, Palbociclib and Fulvestrant in Advanced Hormone Receptor Positive, FGFR1/2/3-positive Breast Cancer: Phase I Clinical Trial Plus an Expansion Cohort
Brief Summary This study is an open, multicenter, prospective phase I dose escalation clinical trial followed by an expansion cohort. The aim of this study is to asses the Recommended Phase 2 Dose (R2PD) and the safety profile, among other efficacy, in FGFR1/2/3 positive, hormone receptor-positive breast cancer (HRPBC) patients with metastatic disease after progression to the combination of an aromatase inhibitor plus palbociclib, abemaciclib or ribociclib, according RECIST 1.1 criteria.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:
Open label, prospective, multicenter, single-arm, phase I dose-escalation study.
Masking: None (Open Label)
Primary Purpose: Other
Condition  ICMJE
  • Breast Cancer Metastatic
  • Hormone Receptor Positive Malignant Neoplasm of Breast
Intervention  ICMJE Drug: Combination, Rogaratinib + palbociclib + fulvestrant

Patients will receive rogaratinib, palbociclib and fulvestrant in cycles of 28 days.

Escalation Dose will follow a classic 3+3 schedule.The planned dose-levels are as follows:

  • Level 1: Rogaratinib 400 mg PO BID + standard fulvestrant 500 mg every 2nd weeks until the start of the 2nd cycle, becoming every 4 weeks + palbociclib 100 mg PO per day until day 22 followed by a 7-day rest, escalable to 125 mg per day in cycle 2 (N = 3 patients).
  • Level 2: Rogaratinib 600 mg PO BID + fulvestrant 500 mg IM every 2nd weeks until the start of the 2nd cycle, becoming every 4 weeks + palbociclib 100 mg PO per day until day 22 followed by a 7-day rest, escalable to 125 mg per day in cycle 2 (N = 6 patients).

Treatment will continue until disease progression.

Study Arms  ICMJE Experimental: Rogaratinib + palbociclib + fulvestrant
Intervention: Drug: Combination, Rogaratinib + palbociclib + fulvestrant
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: July 22, 2020)
19
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE October 3, 2022
Estimated Primary Completion Date October 3, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Women ?18 years-old.
  2. Diagnostic of metastatic or locally advanced non-resectable breast cancer.
  3. Ability to understand and signing of the PIS/ICF for FGFR testing. FGFR testing will be performed centrally at CNIO (RNAscope and FISH).
  4. Ability to understand and signing the written PIS/ICF for study treatment eligibility.
  5. Availability of fresh tumor biopsy specimen for FGFR1/3 mRNA expression and FISH testing.
  6. Hormone-receptor positivity defined by at least 5% positivity of ER and/or PR (no central laboratory testing is required).
  7. Positivity of FGFR1/2/3 by RNA-scope and/or FISH.
  8. Patients must have undergone a previous hormonal treatment line for metastatic disease, with anastrozole, letrozole or exemestane, plus a cell cycle inhibitor (palbociclib, ribociclib or abemaciclib).
  9. Recovery of toxicities from previous regimens to equal or below tolerable grade II.
  10. HER2-negativity (Herceptest 0+, 1+ or 2+ with negative FISH/CISH/SISH).
  11. ECOG performance status of 0/1.
  12. Life expectancy of >24 weeks.
  13. Adequate bone marrow, liver and renal function as assessed by laboratory requirements:

    1. Absolute neutrophil count (ANC) ? 1,500/mm3
    2. Hemoglobin ? 10 g/dL (without transfusion or erythropoietin .
    3. Platelet count ? 100,000/mm3
    4. Total bilirubin ? 1.5 × the upper limit of normal (ULN).
    5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 × ULN
    6. Alkaline phosphatase ? 2.5 times ULN
    7. Lipase and amylase ? 2 × ULN.
    8. Serum albumin ? 2.5 g/dl.
    9. Glomerular filtration rate (GFR) ? 60 mL/min/1.73 m2
  14. INR ? 1.5 × ULN and PTT or activated PTT (aPTT) ? 1.5 × ULN.
  15. Negative serum pregnancy test in women of childbearing potential.
  16. Women of reproductive potential must agree to use highly effective contraception when sexually active.
  17. Evaluable disease according to RECIST 1.1 criteria.

Exclusion Criteria:

  1. Involvement in the planning and/or conduct the study.
  2. Previous enrollment in the present study.
  3. Previous or concurrent cancer except:

    1. Cervical carcinoma in situ.
    2. Treated basal-cell carcinoma or squamous cell skin cancer.
    3. Any other cancer curatively treated > 3 years before the first study drug administration.
  4. Receipt the last dose of anticancer therapy at least 21 days prior to the first dose of study drug.
  5. Acute toxic effects of previous anticancer chemotherapy or immunotherapy have to be normalized completely
  6. Anti-cancer therapy is defined as any agent or combination of agents with clinically proven anti-tumor activity
  7. Previous treatment with anti-FGFR directed therapies.
  8. Irradiation of single bony lesions with risk of fracture. Zoledronic acid or denosumab started prior to trial registration is allowed.
  9. Symptomatic metastatic brain or meningeal tumors.
  10. History or current condition of an uncontrolled cardiovascular disease including any of the following conditions:

    1. Congestive heart failure, unstable angina (symptoms of angina at rest) or
    2. New-onset angina
    3. Myocardial infarction (MI).
    4. Unstable cardiac arrhythmias requiring anti-arrhythmic therapy.
    5. Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, must be on a stable medical regimen.
  11. Known human immunodeficiency virus (HIV) infection.
  12. Active hepatitis B virus or hepatitis C infection requiring treatment.

    1. Patients with past HBV infection or resolved HBV infection are eligible if HBV DNA is negative.
    2. Patients positive for hepatitis C virus are eligible only if polymerase chain reaction is negative for HCV RNA.
  13. Any condition that in the opinion of the investigator would interfere with evaluation of study treatment or interpretation of patient safety or study results, or inability to comply with the study and follow-up procedures.
  14. Previous or concomitant participation in another clinical study with investigational medicinal products.
  15. Active tuberculosis.
  16. Clinically active infections.
  17. Treatment with therapeutic oral or i.v. antibiotics.
  18. Patients receiving prophylactic antibiotics are eligible.
  19. Seizure disorder requiring medication.
  20. History of organ allograft.
  21. Evidence or history of bleeding diathesis or coagulopathy.
  22. Any hemorrhage / bleeding event CTCAE v.5.0 ? Grade 3.
  23. Serious, non-healing wound, ulcer or bone fracture.
  24. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation.
  25. Any malabsorption condition.
  26. Current diagnosis of any retinal disorders including retinal detachment, retinal pigment epithelial detachment (RPED), serous retinopathy or retinal vein occlusion.
  27. Peripheral sensory neuropathy of CTCAE v.5.0 Grade 2 or higher.
  28. Current evidence of endocrine alteration of calcium phosphate homeostasis.
  29. Concomitant therapies that are known to increase serum phosphate levels.
  30. Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study.
  31. Breast-feeding.
  32. Use of strong inhibitors of CYP3A4 and strong inducers of CYP3A4.
  33. Autologous bone marrow transplant or stem cell rescue.
  34. Major surgery, open biopsy or significant traumatic injury.
  35. Renal failure requiring peritoneal dialysis or hemodialysis.
  36. Systolic/diastolic blood pressure ? 100/60 mmHg and concurrent heart rate ? 100/min.
  37. Inability to swallow oral tablets.
  38. Close affiliation with the investigational site; e.g. a close relative of the investigator or a dependent person.
  39. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
  40. Arterial or venous thrombotic events or embolic events such as cerebrovascular accident, deep vein thrombosis or pulmonary embolism.
Sex/Gender  ICMJE
Sexes Eligible for Study:Female
Gender Based Eligibility:Yes
Gender Eligibility Description:In this case gender is important because it is a specific cancer in women.
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Miguel Ángel Quintela-Fandino, MD+34917328000[email protected]
Listed Location Countries  ICMJE Spain
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04483505
Other Study ID Numbers  ICMJE ROGABREAST
2020-000055-12 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Fundacion CRIS de Investigación para Vencer el Cáncer
Study Sponsor  ICMJE Fundacion CRIS de Investigación para Vencer el Cáncer
Collaborators  ICMJE
  • Bayer
  • Pfizer
  • Apices Soluciones S.L.
Investigators  ICMJE
Principal Investigator:Miguel Ángel Quintela-FandinoCentro Nacional de Investigaciones Oncológicas
Principal Investigator:Luis Manso, MDHospital Universitario 12 de Octubre
Principal Investigator:Ramón Colomer i BoschFundación de Investigación Biomédica - Hospital Universitario de La Princesa
PRS Account Fundacion CRIS de Investigación para Vencer el Cáncer
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP